Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | BACE1 | P56817 | 7/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | NPY4R | P50391 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528212 | 0.96 | OPRD1 (0.57) | OPRD1OPRM1NPY1RNPY2RNPY4R | |
| SCHEMBL30974023 | 0.93 | OPRD1 (0.59) | OPRD1OPRM1BACE1CASP1BACE2 | |
| SCHEMBL30373869 | 0.90 | OPRD1 (0.61) | OPRD1BACE1CASP1BACE2 | |
| SCHEMBL30252365 | 0.89 | MME (0.51) | OPRD1OPRM1BACE1NPY1RNPY2R | |
| SCHEMBL29697013 | 0.89 | MME (0.51) | OPRD1OPRM1BACE1NPY1RNPY2R | |
| SCHEMBL31410863 | 0.89 | OPRD1 (0.54) | OPRD1OPRM1BACE1CASP1BACE2 | |
| SCHEMBL31028236 | 0.88 | OPRD1 (0.49) | OPRD1OPRM1NPY1RNPY2RNPY4R | |
| SCHEMBL29772603 | 0.88 | OPRD1 (0.58) | OPRD1OPRM1BACE1BACE2NPY1R | |
| SCHEMBL29976107 | 0.88 | PDCD1LG2 (0.57) | OPRD1OPRM1NPY1RNPY2RNPY4R | |
| SCHEMBL31319516 | 0.88 | BACE1 (0.59) | OPRD1BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263480-A1 | Clazakizumab in the Treatment of Chronic Antibody-Mediated Rejection of Organ Transplant | CEDARS-SINAI MEDICAL CENTER (US) | 2025-08-21 | — | — | US | disclosed |
| CN-112969711-B | Desensitization and improvement of kidney transplantation in HLA sensitized patients using cladagumab | 西达赛奈医疗中心 | 2024-12-17 | — | — | CN | disclosed |
| CN-113194996-B | Clazazumab for the treatment of chronic antibody-mediated organ transplant rejection | 西达赛奈医疗中心 | 2024-06-28 | — | — | CN | disclosed |
| US-20220073605-A1 | CLAZAKIZUMAB IN THE TREATMENT OF CHRONIC ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANT | CEDARS-SINAI MEDICAL CENTER (US) | 2022-03-10 | — | — | US | disclosed |